Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
Authors:
- Camila Castillo-FerrerCCCamila Castillo-Ferrer
- Théo MarguetTMThéo Marguet
- Laetitia VanwonterghemLVLaetitia Vanwonterghem
- Sule ErbekSESule Erbek
- Florent ChuffartFCFlorent Chuffart
- Stéphane MouretSMStéphane Mouret
- Sabiha Trabelsi MessaiSMSabiha Trabelsi Messai
- Anne-Sophie GauchezAGAnne-Sophie Gauchez
- Jean-Luc CollJean-Luc Coll
- Julie CharlesJCJulie Charles
- Amandine HurbinAHAmandine Hurbin
- Véronique Martel-FrachetVMVéronique Martel-Frachet
- 12 August 2023
- journal article
- letter
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Abstract
No abstract availableFunding Information
- Agence Nationale de la Recherche (ANR-15-IDEX-02)
- Ligue Nationale Contre le Cancer
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
This publication has 14 references indexed in Scilit:
- Circulating insulin‐like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutritionInternational Journal of Cancer, 2018
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signallingNature Communications, 2018
- Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapyOncotarget, 2017
- Reference Values for IGF-I Serum Concentrations: Comparison of Six ImmunoassaysThe Journal of Clinical Endocrinology & Metabolism, 2016
- Therapy-induced tumour secretomes promote resistance and tumour progressionNature, 2015
- Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationCellular and Molecular Life Sciences, 2013
- The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase‐dependent mechanismInternational Journal of Cancer, 2013
- Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK InhibitionJournal of Investigative Dermatology, 2012
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAsOncogene, 2006